Verada is the first operations layer for innovative interventions entering the UK. We support innovative medical devices and medicinal product companies across neuro, musculoskeletal, and cognitive care, from regulatory strategy through to real-world evidence and commercial adoption.
In medical innovation, earning a UKCA or CE mark should be the beginning of a technology's clinical life. Too often it's where progress stalls, proven interventions stranded on the wrong side of a fragmented, risk-averse system while patients lose the treatment windows that matter most.
Verada is an integrated adoption engine: a single group that carries proven medical innovation all the way from first UK deployment to scaled, reimbursed care. Beneath the group sit three focused operating companies, each strengthening the others.
The connective layer that holds everything together: group strategy, market-access direction, evidence governance, and the shared clinical infrastructure every company reuses. It's what lets each new technology follow the same proven route rather than starting from zero. Beneath it sit three focused operating companies:
The unifying layer that brings together multimodal data across care settings and clinical trial units. It identifies and characterises real-world patient cohorts from routine EHR data, captures the full spectrum of trial outcomes (patient-, clinician-, and performance-reported), and structures it all into evidence-ready clinical intelligence: the backbone the whole group runs on.
A next-generation CRO running decentralised trials across neuro/CNS, musculoskeletal, and cognitive indications. It spans devices, small molecules, biologics, and ATMPs (cell & gene therapies), plus nutraceuticals and nootropics where they target cognitive endpoints, capturing molecular, physiological, psychological, and functional outcomes.
A CQC-registered service delivering both rehabilitative and regenerative interventions across neuro/CNS, musculoskeletal, and cognitive conditions. Efficacy-proven interventions generate the Phase IV, real-world evidence that carries them to routine, reimbursed adoption. The group's first customer, its revenue generator, and its evidence layer.
The group's defensibility isn't in any single layer: it's in the interlock. Delivering care generates exclusive, longitudinal rehabilitation data. That data sharpens the models and clinical protocols. Better outcomes win the trust of payers and open channel access. And that access drives more delivery.
Every turn of the loop deepens all of it at once: data that can't be acquired retrospectively, evidence in the formats commissioners already trust, and a route to market that gets harder to replicate with each patient treated.
The hard work is done once and amortised across the whole portfolio. Each new medical technology follows the same repeatable route, reusing the clinical infrastructure, evidence engine, and market-access playbook already in place.
Study design, evidence-pathway build, and grant navigation: laying the groundwork before a single patient is seen.
Feasibility and acceptability studies that qualify the intervention, de-risk workflow fit, and prepare higher-order trials where warranted.
Clinic-led patient deployment within Verada's own care delivery: creating early revenue, operational proof, and live outcomes data at once.
Real-world evidence unlocks the route to market: private-provider uptake, payer engagement, and NHS commissioning at population scale.
Verada is led by a team spanning healthcare delivery, medical-device regulation, rehabilitation science, and health-data governance, bringing together the clinical, regulatory, and technical depth the group runs on.
Verada is de-risking ahead of build, securing partners and non-dilutive funding before any private capital is raised. Early progress across the group:
Memoranda of understanding with two proven medical-device partners, establishing Verada's first technologies for UK adoption.
Working with Northumbria University and the University of the West of England, Bristol on our feasibility programme.
Public funding sought to support our initial feasibility study, validating the model with non-dilutive research funding ahead of any private raise.
Verada is building durable infrastructure at the intersection of medical technology, regulated care, and clinical evidence, a model designed to compound in value with every patient treated. If you invest in health technology, back founders solving hard adoption problems, or want to explore partnership, we'd welcome a conversation.
Connect with our founder →